AUPH - Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

• The European Commission has approved Aurinia Pharmaceuticals' ( NASDAQ: AUPH ) Lupkynis (voclosporin) for lupus nephritis.
• The approval triggers a $30M milestone payment from partner Otsuka Pharmaceutical ( OTCPK:OTSKF )( OTCPK:OTSKY ).
• A decision on Lupkynis in the UK is expected in the coming weeks.
• Lupkynis won US FDA approval in January 2021. In August, Aurinia projected 2 022 revenue of the drug of $115M-$135M .
• Seeking Alpha's Quant Rating views Aurinia ( AUPH ) as a strong sell.

For further details see: